Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $10.00 to $7.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $2.73 and last traded at $2.7050, with a volume of 8,315,663 shares traded. The stock had previously closed at $2.90.
A number of other equities analysts have also recently weighed in on RXRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a research note on Friday, October 16th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.58.
View Our Latest Analysis on Recursion Pharmaceuticals
Insider Buying and Selling at Recursion Pharmaceuticals
In related news, Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the transaction, the director directly owned 6,108,287 shares in the company, valued at approximately $29,564,109.08. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock valued at $701,276 over the last quarter. 6.65% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of large investors have recently made changes to their positions in the stock. Jump Financial LLC lifted its position in Recursion Pharmaceuticals by 145.0% during the third quarter. Jump Financial LLC now owns 2,497,200 shares of the company’s stock worth $10,313,000 after buying an additional 1,478,027 shares in the last quarter. First Trust Advisors LP grew its holdings in Recursion Pharmaceuticals by 16.8% in the 3rd quarter. First Trust Advisors LP now owns 3,551,885 shares of the company’s stock valued at $14,669,000 after buying an additional 510,056 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth $243,000. Voya Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 258.7% in the 3rd quarter. Voya Investment Management LLC now owns 351,438 shares of the company’s stock worth $1,451,000 after acquiring an additional 253,455 shares during the last quarter. Finally, HighTower Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 133.6% during the 3rd quarter. HighTower Advisors LLC now owns 99,268 shares of the company’s stock worth $410,000 after acquiring an additional 56,782 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Stock Performance
The firm’s 50-day moving average price is $3.76 and its two-hundred day moving average price is $3.48. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -2.95 and a beta of 1.15.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22). The company had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same period in the previous year, the firm earned ($0.36) earnings per share. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
